# Restoring T-Cell Activity via PD-1 Blockade ## How does PD-1 blockade restore T-cell activity in pembrolizumab-treated tumors? PD-1 blockade restores T-cell activity by releasing PD-1-mediated suppression of preexisting exhausted tumor-infiltrating lymphocytes, enabling IFN-γ signaling that drives their clonal expansion, proliferation, and cytotoxic function. ## Abstract PD-1 blockade restores T-cell activity primarily through activation of preexisting tumor-infiltrating lymphocytes rather than recruitment of new T-cell clones. Across melanoma and head and neck cancer, restoration occurred via clonal expansion of exhausted CD8+ TILs with tissue-resident memory programs, increased CD8+ memory T cells, and enhanced granzyme B and Ki67 expression indicating proliferation and cytotoxic capacity. Mechanistically, this operated through release of PD-1-mediated suppression, enabling IFN-γ signaling pathways that drove T-cell proliferation, antigen presentation, and cytotoxic function. In head and neck cancer, restoration was further supported by enhanced K+ channel activity and Ca2+ signaling, which provided metabolic infrastructure for sustained T-cell activity. Restoration proceeded rapidly—within 5 weeks—through a biphasic pattern of immediate metabolic changes followed by durable functional enhancement. However, in pancreatic cancer, while PD-1 blockade successfully reactivated T cells as evidenced by increased cell cycle entry and IFNγ signature, concurrent upregulation of NF-κB signaling counteracted these benefits, demonstrating that successful restoration requires absence of alternative inhibitory pathways. Baseline tumor immune composition determined restoration capacity across all cancer types studied. Responding tumors had higher baseline densities of CD8+, PD-1+, and PD-L1+ cells at tumor margins, preexisting ZNF683+CTX+ TILs, and T cell-inflamed gene expression signatures. The degree of T-cell restoration correlated directly with clinical outcomes, as proliferating intratumoral CD8+ T cells correlated with radiographic tumor reduction and enhanced functional measures associated with durable responses. These findings indicate that PD-1 blockade does not generate de novo antitumor responses but reinvigorates existing exhausted T cells, making adequate baseline T-cell infiltration a prerequisite for clinical benefit. ## Methods We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question. ### Paper search We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of [Semantic Scholar](https://www.semanticscholar.org/) and [OpenAlex](https://openalex.org/). We ran this query: "How does PD-1 blockade restore T-cell activity in pembrolizumab-treated tumors?" The search returned 200 total results from Elicit. ### Screening We screened in sources based on their abstracts that met these criteria: - **Patient Population**: Does the study involve patients with any type of malignant tumor? - **Pembrolizumab Treatment**: Does the study include pembrolizumab administered as monotherapy or combination therapy? - **T-cell Functional Measurements**: Does the study measure T-cell functional parameters (such as proliferation, cytokine production, cytotoxic activity, or T-cell infiltration) before and/or after pembrolizumab treatment? - **Sample Analysis Type**: Does the study include tumor tissue analysis or peripheral blood T-cell analysis? - **Study Design**: Is the study a randomized controlled trial, cohort study, case-control study, case series with ≥5 patients, systematic review, or meta-analysis? - **Immunological Data Inclusion**: Does the study report immunological or T-cell functional data (not solely clinical outcomes like response rates or survival)? - **Pembrolizumab-Specific Data**: Does the study include pembrolizumab data (not focusing solely on other PD-1 inhibitors like nivolumab or cemiplimab without pembrolizumab data)? - **Human Clinical Samples**: Does the study use human tumor samples from pembrolizumab-treated patients (not solely in vitro cell line studies without clinical samples)? - **Cancer Patient Population**: Does the study focus on cancer patients (not solely healthy volunteers or non-cancer populations)? ## Data extraction We asked a large language model to extract each data column below from each paper. - **Study Population**: Extract patient and tumor characteristics relevant to PD-1 blockade and T-cell restoration, including: - Cancer type and stage - Sample size - Baseline T-cell infiltration status or immune phenotype - Prior treatments that could affect T-cell function - Patient demographics if relevant to immune response - **Pembrolizumab Protocol**: Extract pembrolizumab treatment details including: - Dosing regimen and schedule - Treatment duration or number of cycles - Combination with other therapies (chemotherapy, radiation, other immunotherapies) - Timing of sample collection relative to treatment (baseline, on-treatment, post-treatment) - **T-Cell Activity Measures**: Extract all measures of T-cell activity and function that were assessed for restoration by PD-1 blockade, including: - Specific T-cell functions measured (cytotoxicity, proliferation, migration, cytokine production, etc.) - T-cell phenotypes and activation markers (CD8+, memory subsets, exhaustion markers like PD-1, activation markers) - Functional assays used (flow cytometry panels, functional tests, gene expression) - Baseline vs. post-treatment changes in these measures - **Restoration Mechanisms**: Extract mechanistic findings about HOW PD-1 blockade restores T-cell activity, including: - Molecular pathways identified (NF-κB, IFN-γ signaling, etc.) - Cellular mechanisms (reversal of exhaustion, memory cell expansion, etc.) - Ion channel or metabolic changes affecting T-cell function - Gene expression changes related to T-cell restoration - Any proposed causal mechanisms for the restoration process - **Predictive Biomarkers**: Extract biomarkers or signatures that predict or correlate with T-cell restoration by pembrolizumab, including: - Baseline immune signatures or gene expression profiles - T-cell phenotype markers that predict response - Changes in immune cell ratios (CD8/Treg, etc.) - Early indicators of T-cell reinvigoration - Any validated or proposed biomarker assays for restoration - **Anatomical Patterns**: Extract where T-cell restoration occurs and any location-specific differences, including: - Tumor tissue vs. peripheral blood vs. other anatomical sites - Differences in restoration patterns between locations - Migration or trafficking of restored T-cells - Comparison of intratumoral vs. circulating T-cell changes - **Clinical Correlations**: Extract relationships between T-cell restoration and clinical outcomes, including: - Correlation between degree of T-cell restoration and treatment response - Differences in restoration patterns between responders vs. non-responders - Association between specific restoration mechanisms and survival outcomes - Whether restoration predicts long-term treatment benefit ### Results ## Characteristics of Included Studies All 10 sources examined T-cell restoration mechanisms following pembrolizumab treatment across diverse cancer types. The studies varied in cancer type, sample size, treatment protocols, and analytical approaches. ### Mechanisms of T-Cell Restoration #### Reversal of Exhaustion and Memory Cell Expansion PD-1 blockade restored T-cell function primarily through reversal of exhaustion in preexisting tumor-specific T cells. In HNSCC, responding tumors contained clonally expanded exhausted CD8+ TILs with tissue-resident memory programs characterized by high cytotoxic potential (CTX+) and ZNF683 expression at baseline. Treatment activated these preexisting CTX+ZNF683+CD8+ TILs, paralleling loss of viable tumor. This revival of preexisting ZNF683+CTX+ TILs was identified as a major mechanism of response. ### Molecular Signaling Pathways Multiple molecular pathways mediated T-cell restoration. IFN-γ signaling emerged as a central driver across studies. PD-1 blockade induced an IFNγ signature characterized by IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance. This included upregulation of HLA molecules, immunoproteosome components, and checkpoint inhibitors like PD-L1 and PD-L2. Activation of downstream signaling molecules like STAT1 and CMKLR1 was also observed. ### Ion Channel and Metabolic Mechanisms In HNSCC, pembrolizumab enhanced T-cell function through increased K+ channel activity and Ca2+ signaling. Treatment increased KCa3.1 and Kv1.3 channel activity in both TILs and peripheral blood T cells. These ion channel changes were accompanied by improved Ca2+ fluxing abilities, which are crucial for T-cell cytotoxicity and chemotaxis. The molecular pathway involving increased K+ channel activity and Ca2+ fluxes enhanced T-cell cytotoxic potential and migratory ability. Importantly, reversal of exhaustion was demonstrated by improved chemotaxis in an adenosine-rich environment, indicating restoration of function even in immunosuppressive contexts. ### Predictive Biomarkers for T-Cell Restoration #### Baseline Immune Signatures Baseline immune phenotypes strongly predicted restoration capacity. In HNSCC, high numbers of CD103+PD-1+CD8+ T cells infiltrating pretreatment lesions predicted response. The presence of ZNF683+CD8+ T cells with high cytotoxic potential and tissue-resident memory programs at baseline distinguished responders from nonresponders. Conversely, nonresponder baseline tumor microenvironments exhibited relative absence of ZNF683+CTX+ TILs. #### Gene Expression Profiles A T cell-inflamed gene expression profile (GEP) emerged as a pan-tumor predictive biomarker across 9 cancer types in 220 patients. This preliminary IFN-γ signature (10 genes), expanded to a preliminary expanded immune signature (28 genes), and was refined to a final 18-gene profile. The T cell-inflamed GEP contained genes related to cytolytic activity, cytokines/chemokines, T cell markers, NK cell activity, antigen presentation, and immunomodulatory factors. This signature included IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance and was developed into a clinical-grade assay. ### Anatomical Patterns of T-Cell Restoration #### Intratumoral vs. Circulating Compartments T-cell restoration occurred in distinct patterns across anatomical compartments. Within tumor tissue, responding melanoma patients showed proliferation of intratumoral CD8+ T cells that directly correlated with radiographic reduction in tumor size. T-cell density increased in parallel at both the invasive margin and tumor center. The increase in CD8+ T cells was directly correlated with radiographic tumor reduction, and proliferating CD8/Ki67 double-positive cells were restricted to tumor parenchyma. In HNSCC, restoration occurred within the tumor microenvironment through clonal expansion and activation of preexisting tumor-infiltrating lymphocytes. Response was associated with high numbers of CD103+PD-1+CD8+ T cells infiltrating pretreatment lesions. The primary anatomical pattern involved intratumoral changes rather than circulating modifications. ### Temporal Dynamics of T-Cell Restoration #### Rapidity of Restoration T-cell restoration occurred rapidly after pembrolizumab initiation. In HNSCC, pathologic responses occurred after 5 weeks of PD-1 blockade, with activation of preexisting CTX+ZNF683+CD8+ TILs observed in the immediate postneoadjuvant setting. ### Clinical Correlations #### Response Prediction and Survival The degree of T-cell restoration strongly correlated with clinical outcomes. In HNSCC, responding tumors had clonally expanded ZNF683+CTX+CD8+ TILs, while nonresponders lacked these cells. Revival of preexisting ZNF683+CTX+ TILs was a major mechanism of response. ## Synthesis The available evidence reveals consistent mechanisms of T-cell restoration across most cancer types studied, with one notable exception requiring mechanistic explanation. The T cell-inflamed phenotype emerged as necessary but not always sufficient for clinical benefit. Baseline intratumoral T-cell infiltration improved response likelihood, with validated biomarkers including CD8 expression at invasive margins and the 18-gene T cell-inflamed GEP. However, even tumors with baseline T-cell infiltration could fail to respond if other suppressive mechanisms like NF-κB signaling or insufficient cytotoxic potential were present. Among responding tumors, the degree of restoration correlated with magnitude of clinical benefit: proliferating intratumoral CD8+ T cells directly correlated with radiographic tumor reduction, and enhanced K+ channel activity associated with durable responses. This dose-response relationship between T-cell functional restoration and tumor regression supports a causal rather than merely correlative relationship.